Cancer Medicines Outcomes Programme Public Health Scotland (CMOP-PHS) report
First-line treatment of adults with HER2-positive metastatic breast cancer (NCMAG125)

About this release

The aim of this work was to capture real-world evidence (RWE) from Scotland on the use of first-line systemic anti-cancer therapy (SACT) for adult patients with HER2+ metastatic breast cancer. This work will enable NCMAG members to assess the relevance of information, provided as part of the assessment process, to patients in Scotland.

This work was requested by the National Cancer Medicines Advisory Group (NCMAG) to support their decision-making processes. NCMAG are assessing the use of weekly paclitaxel in combination with pertuzumab and trastuzumab for the first-line treatment of HER2-positive (HER2+) metastatic breast cancer (NCMAG125). Details of the presumptions made to identify this cohort are described in Section 2.3.1. of the main report. This work will enable NCMAG members to assess the relevancy of information, provided as part of the assessment process, to patients in Scotland.

The objectives of this work were to:

• Determine the number of patients prescribed SACT as first-line treatment for HER2+ metastatic breast cancer
• Describe SACT usage for first-line treatment of HER2+ metastatic breast cancer
• Describe the baseline characteristics of patients prescribed SACT for first-line treatment of HER2+ metastatic breast cancer
• Describe the treatment characteristics including duration of treatment for first-line treatment of HER2+ metastatic breast cancer.